Taysha Gene Therapies, Inc. Common Stock
TSHATaysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodegenerative diseases and monogenic rare disorders. Founded with a mission to deliver transformative treatments, Taysha leverages its proprietary platform to develop innovative viral vector-based therapies aimed at addressing the underlying causes of these conditions. The company collaborates with academic institutions and industry partners to advance its pipeline of potential treatments.
Company News
Taysha Gene Therapies priced an underwritten public offering of 32.5 million shares at $6.00 per share and pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The offering is expected to close on June 26, 2026. The company is a clinical-stage biotech focused on AAV-based gene therapies for CNS diseases, with its l...
Taysha Gene Therapies announced it will report Q1 2026 financial results and host a conference call on May 6, 2026. The clinical-stage biotech company is advancing AAV-based gene therapies for severe CNS monogenic diseases, with its lead program TSHA-102 in development for Rett syndrome.
Taysha Gene Therapies announced that on April 1, 2026, its Compensation Committee granted four new employees a total of 300,000 restricted stock units and options to purchase 92,400 shares at an exercise price of $4.31. The grants were made under the company's 2023 Inducement Plan as part of their employment agreements.
Taysha Gene Therapies reported full-year 2025 net loss of $109.0 million and announced significant progress in its lead program TSHA-102 for Rett syndrome treatment. The company has dosed multiple patients in its REVEAL pivotal trial and received FDA clearance for the ASPIRE trial in younger patients (ages 2-4). TSHA-102 maintained a favorable sa...
Taysha Gene Therapies announced that its Compensation Committee granted 349,000 restricted stock units to three new employees on February 2, 2026, as an inducement for employment. The RSUs will vest in four equal annual installments over four years, subject to continued service with the company.
